$20.28 B
Share price
Change (1 day)
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total assets

Total assets on the balance sheet as of September 2023 : $5.52 B

According to BeiGene 's latest financial reports the company's total assets are $5.52 B. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

BeiGene - Total assets on balance sheet (from 2014 to 2023)

Total assets by year

Year Total assets Change
2022-12-31$6.37 B-26.22%
2021-12-31$8.64 B54.37%
2020-12-31$5.60 B247.38%
2019-12-31$1.61 B-28.33%
2018-12-31$2.24 B114.98%
2017-12-31$1.04 B157.87%
2016-12-31$0.40 B247.55%
2015-12-31$0.11 B117.76%
2014-12-31$53.62 M354.49%
2013-12-31$11.79 M

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
$2.05 B-62.77%๐Ÿ‡บ๐Ÿ‡ธ USA
$30.46 M-99.45%๐Ÿ‡บ๐Ÿ‡ธ USA